AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9329511
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, each given orally four times daily for 1 week) followed by naproxen (750 mg daily for 8 weeks)
Trial: 2663937
Drug: Topical ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketanserin (2% ointment)
Trial: 194691
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Trial: 194691
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (cyclophosphamide, methotrexate, CCNU)
Trial: 31743533
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.25 mg/kg preoperatively, followed by 0.25 mg/kg/hr intraoperatively, and 0.1 mg/kg/hr from 1 hr before the end of surgery until the end of recovery room stay
Trial: 26076867
Drug: avibactam 500
RxNorm normalized name: avibactam 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: avibactam 500 mg
Trial: 26076867
Drug: ceftazidime 2000
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime 2000 mg plus avibactam 500 mg
Trial: 23260506
Drug: Physician management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician management plus cognitive behavioral therapy
Trial: 22980100
Drug: Community-based psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based psychosocial intervention consisting of 12 sessions (30 minutes of relaxation exercises and 75 minutes of structured support groups) delivered twice per week over six weeks.
Trial: 15361773
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion (10, 20 and 40 ng/kg per min for 30 min)
Trial: 9863121
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs combined with chemotherapy
Trial: 3528087
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + MISO (400 mg/M2 2‐4 hours prior to RT daily, maximum 12 gm/M2)
Trial: 24045440
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by local therapy (radiation and/or surgery) and adjuvant chemotherapy
Trial: 24045440
Drug: Chemotherapy/surgery alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/surgery alone
Trial: 18564626
Drug: Etoricoxib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (45 mg on day 2, 90 mg on day 3)
Trial: 16033730
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (premeal)
Trial: 16033730
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (postmeal)
Trial: 16033730
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (premeal)
Trial: 12472702
Drug: Methohexital (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (10 mg.ml‐1) combined with remifentanil (6.67 micro g.ml‐1)
Trial: 10051728
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP) 200 microg once daily for 4 weeks
Trial: 10051728
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP)
Trial: 2140546
Drug: Clarithromycin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (two 250 mg tablets twice daily)
Trial: 2140546
Drug: Amoxycillin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (two 500 mg capsules twice daily)
Trial: 28892233
Drug: HA microneedle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA microneedle patch
Trial: 23689006
Drug: Revascularization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization treatment with calcium hydroxide
Trial: 11367972
Drug: Listerine Antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine Antiseptic (L)
Trial: 3595068
Drug: Fasting (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting (10 mg nifedipine)
Trial: 3595068
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (10 mg nifedipine)
Trial: 3595068
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (10 mg nifedipine)
Trial: 31886707
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide (500 mg/day)
Trial: 30176845
Drug: Systematic self-monitoring
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systematic self-monitoring (5 times per day) and weekly personalized feedback on positive affect and activities ("Do"-module)
Trial: 30176845
Drug: Systematic self-monitoring
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systematic self-monitoring (5 times per day) and weekly personalized feedback on negative affect and thinking patterns ("Think"-module)
Trial: 24407896
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with TCI (Group A)
Trial: 21312290
Drug: Amantadine (100-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100-150 mg/day depending on weight)
Trial: 21312290
Drug: Methylphenidate (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20-30 mg/day)
Trial: 18186057
Drug: Biological/genetic explanation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/genetic explanation of anorexia nervosa
Trial: 16817177
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg abciximab bolus administered early in the emergency department
Trial: 16817177
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg abciximab bolus administered late in the catheterization laboratory
Trial: 12538427
Drug: L‐NMMA (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (NO synthase inhibitor)
Trial: 12538427
Drug: Vascular cell
RxNorm normalized name: Autologous stromal vascular cell fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular cell adhesion molecule-1
Trial: 1658648
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange twice weekly for three weeks
Trial: 30779333
Drug: SMART-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART-based treatment (online lessons, self-monitoring, feedback, monthly weigh-ins)
Trial: 30779333
Drug: GROUP-based treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GROUP-based treatment (weekly meetings for 6 months, biweekly for 6 months, monthly for 6 months, self-monitoring via paper diaries with written feedback)
Trial: 30779333
Drug: CONTROL (self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONTROL (self-monitoring via paper diaries with written feedback and monthly weigh-ins)
Trial: 28134840
Drug: A2 milk
RxNorm normalized name: Pure Bliss A2 Milk Infant Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2 milk (500 mL)
Trial: 28134840
Drug: Regular milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular milk (500 mL)
Trial: 28134840
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) (500 mL)
Trial: 28134840
Drug: Milk treatments
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk treatments (A2 and regular)
Trial: 23283923
Drug: Xylitol lozenges
RxNorm normalized name: xylitol Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol lozenges (5 lozenges of 1.0 gram daily for 33 months)
Trial: 23283923
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (5 lozenges daily for 33 months)
Trial: 20868639
Drug: Extended dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dosing (every second day)
Trial: 20868639
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing (usual medication)
Trial: 15796091
Drug: PMBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMBL treatment (sublingual tablet taken for ten consecutive days over three consecutive months)
Trial: 15796091
Drug: PMBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMBL treatment
Trial: 15796091
Drug: Device for
RxNorm normalized name: vibrating transient device for constipation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device for PMBL treatment
Trial: 11405516
Drug: Self-treatment guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment guidelines (group S)
Trial: 8375243
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (0.25 mg)
Trial: 29023624
Drug: Pedicled buccal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedicled buccal fat pad with Emdogain (group I; n = 5)
Trial: 29023624
Drug: Pedicled buccal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedicled buccal fat pad alone (group II; n = 5)
Trial: 26141306
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 U/mL locks
Trial: 16273330
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (polyethylene glycol; Group 1)
Trial: 16273330
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (Group 2)
Trial: 10632003
Drug: Balanced saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced saline solution (BSS) (group III)
Trial: 10632003
Drug: No adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunct (group IV)
Trial: 9110100
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day for six weeks
Trial: 8237626
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide by intravenous bolus
Trial: 8237626
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide orally
Trial: 8237626
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide (both intravenous and oral)
Trial: 29614960
Drug: Chair based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair based exercise (CCBE) delivered once a week in day centres and community groups, and twice a week in care homes.
Trial: 16034448
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg QD (Treatment phase-1)
Trial: 16034448
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg QD (Treatment phase-2)
Trial: 12047009
Drug: Combination antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antipsychotics (specifically augmentation of clozapine)
Trial: 12047009
Drug: Clozapine (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (as a monotherapy)
Trial: 2193265
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic therapy (cephalexin 500 mg every 6 hours)
Trial: 2193265
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic therapy (cephalothin 1 g every 6 hours)
Trial: 2193265
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and IV)
Trial: 361000
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg every 8 hours when rectal temperature >= 38.5°C)
Trial: 361000
Drug: Phenobarbitone (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (3.5 +/- 1 mg/kg per day)
Trial: 23364373
Drug: Ketamine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine + Atropine (0.01 mg/kg)
Trial: 22193788
Drug: Weekly feedback
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly feedback to clinicians
Trial: 26788345
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 1200 mg
Trial: 15234478
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection (acute pain)
Trial: 15234478
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection (fear of pain)
Trial: 7566020
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg each evening)
Trial: 2190884
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF (5.5 micrograms/kg/day by continuous iv infusion for 14 days)
Trial: 2190884
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CTX) without rhGM-CSF
Trial: 2190884
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF
Trial: 474381
Drug: GIK (30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (30% glucose solution with 50 units of regular insulin and 80 mM KCl per liter, 50 mol. bolus followed by 1 ml./Kg./hr.)
Trial: 474381
Drug: NSS (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS (normal saline, 50 mol. bolus followed by 1 ml./Kg./hr.)
Trial: 31789800
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation (supervised exercise therapy) in addition to standard care (10 days of prednisolone, general information, and counseling)
Trial: 25487899
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gluconate surgical preparation
Trial: 21603893
Drug: Ketamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (100 ng/ml blood plasma level)
Trial: 17394048
Drug: Oral polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polyethylene glycol lavage solution and enemas (group A)
Trial: 17394048
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (group B)
Trial: 15338804
Drug: Daily symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily symptoms
Trial: 15338804
Drug: Asthma symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma symptoms and beta-agonist use
Trial: 9555777
Drug: Oral d-sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d-sotalol
Trial: 27117531
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg Q3W
Trial: 27117531
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg Q3W
Trial: 27117531
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg Q2W
Trial: 23883162
Drug: Anma massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anma massage therapy (40-min session once weekly for 2 months, total of 8 sessions)
Trial: 23883162
Drug: Anma massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anma massage therapy
Trial: 16458680
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (12 argon spots)
Trial: 11182624
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy initiated within 24 hours after the onset of symptoms of an acute MI
Trial: 11182624
Drug: Aspirin in
RxNorm normalized name: Non-Aspirin Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in patients with prior occlusive cardiovascular disease
Trial: 11182624
Drug: Aspirin in
RxNorm normalized name: Non-Aspirin Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in primary prevention trials
Trial: 24986183
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) among older adults
Trial: 18786230
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg teriparatide (PTH 1‐34) daily subcutaneous injections
Trial: 2143597
Drug: Ramipril alone
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril alone (2.5-5 mg/day)
Trial: 2143597
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg in combination with furosemide 20 mg
Trial: 25143337
Drug: Cyclosporine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (3 mg/kg per day for 8 weeks)
Trial: 25143337
Drug: Acitretin (0.3-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (0.3-0.5 mg/kg per day for 8 weeks)
Trial: 15495698
Drug: Bed rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bed rest as a therapy
Trial: 9231668
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who failed treatment
Trial: 29561278
Drug: Lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective ventilation (LPV group) [tidal volume 5 ml/kg ideal body weight + PEEP between 5 and 8 cmH2O]
Trial: 29561278
Drug: Nonprotective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprotective ventilation (control group) [tidal volume 10 ml/kg ideal body weight without PEEP]
Trial: 27108261
Drug: Posterior decompression,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior decompression, bone cement augmentation and internal fixation (n=14)
Trial: 17525884
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (E) - home-based walking program, aerobic walking at target heart rate for 20 minutes or more daily, 2 or more days a week
Trial: 12100806
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (six weekly instructional sessions on bladder training and individualized voiding schedules)
Trial: 12100806
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (after 6 weeks for all women)
Trial: 10344481
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied on one arm/hand 3x daily for 9 days
Trial: 7316527
Drug: Once-daily ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily ultraviolet radiation treatment with coal tar
Trial: 7316527
Drug: Twice-daily ultraviolet
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily ultraviolet radiation treatment with coal tar
Trial: 31006575
Drug: Annual school-based
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual school-based treatment with albendazole